Table 2 Microglia depletion models
Models | Approach | Depletion age and efficiency | References |
|---|---|---|---|
Cx3cr1CreER; Csf1rF/F | Tamoxifen administered by oral gavage at E9.5, E11.5, and E13.5 | E14 (70%) | Anderson et al. 2019 [67] |
Pu.1 -/- (Sfpi−/−) | Genetic knockout | E14 (98%) | Kierdorf et al. 2013 [14] |
TGF-β −/− | Genetic knockout | E10.5 (98%) | Butovsky et al. 2014 [58] |
Csf1r-/- | Genetic knockout | E12.5 (98%) | Ginhoux et al. 2010 [9] |
Csf1rΔFIRE/ΔFIRE | Genetic knockout | E12.5 (95%) | Rojo et al. 2019 [59] |
CSF1R inhibitor | PLX5622 administered to pregnant dam at E3.5 | E15.5 (99%) | Rosin et al. 2018 [60] |
CX3CR1CreER-iDTR | Tamoxifen and diphtheria toxin administered alternately (IP) | P6 (60%), P10 (95%), P14 (98%) | Puñal et al. 2019 [61] |
CD11b-DTR | Inject diphtheria toxin (25ng/g dose, IP) twice at a 12h interval | P3 (10%) | Ueno et al. 2013 [62] |